Literature DB >> 2014440

Tracheobronchitis due to Corynebacterium pseudodiphtheriticum.

T J Craig1, F E Maguire, M R Wallace.   

Abstract

We have presented a case of tracheobronchitis due to C pseudodiphtheriticum in a patient with COPD who was treated with prednisone and apparently was not otherwise immunocompromised. Chronic lung disease seems to predispose to infection with C pseudodiphtheriticum; it can also occur in the immunocompetent host. This organism, when isolated in pure culture, should not be dismissed as a contaminant, but must be considered a possible etiologic agent. Sensitivity of diphtheroids to antibiotics is extremely variable. We believe vancomycin should be used in respiratory tract infections caused by diphtheroids, including C pseudodiphtheriticum, until the results of in vitro antibiotic susceptibility tests are available.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014440     DOI: 10.1097/00007611-199104000-00026

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

1.  Corynebacterium pseudodiphtheriticum: Putative probiotic, opportunistic infector, emerging pathogen.

Authors:  Andreas Burkovski
Journal:  Virulence       Date:  2015       Impact factor: 5.882

Review 2.  Clinical microbiology of coryneform bacteria.

Authors:  G Funke; A von Graevenitz; J E Clarridge; K A Bernard
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

3.  Outbreak of Corynebacterium pseudodiphtheriticum infection in cystic fibrosis patients, France.

Authors:  Fadi Bittar; Carole Cassagne; Emmanuelle Bosdure; Nathalie Stremler; Jean Christophe Dubus; Jacques Sarles; Martine Reynaud-Gaubert; Didier Raoult; Jean-Marc Rolain
Journal:  Emerg Infect Dis       Date:  2010-08       Impact factor: 6.883

Review 4.  Exudative pharyngitis possibly due to Corynebacterium pseudodiphtheriticum, a new challenge in the differential diagnosis of diphtheria.

Authors:  H S Izurieta; P M Strebel; T Youngblood; D G Hollis; T Popovic
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.